These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 2084948

  • 41. In vivo effects of low molecular weight heparins on experimental thrombosis and bleeding.
    Hirsh J.
    Haemostasis; 1986; 16(2):82-6. PubMed ID: 3710297
    [Abstract] [Full Text] [Related]

  • 42. Danaparoid: an antithrombotic agent without major impact on triglyceride hydrolysis capacity in humans.
    van Barlingen HH, van Beek A, Erkelens DW, de Bruin TW.
    J Intern Med; 1997 Aug; 242(2):125-9. PubMed ID: 9279289
    [Abstract] [Full Text] [Related]

  • 43. Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic and anticoagulant effects of heparin and dermatan sulfate.
    Ofosu FA, Fernandez F, Gauthier D, Buchanan MR.
    Semin Thromb Hemost; 1985 Apr; 11(2):133-7. PubMed ID: 3898370
    [No Abstract] [Full Text] [Related]

  • 44. The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity.
    Walenga JM, Bara L, Petitou M, Samama M, Fareed J, Choay J.
    Thromb Res; 1988 Jul 01; 51(1):23-33. PubMed ID: 3166242
    [Abstract] [Full Text] [Related]

  • 45. Pharmacologic properties of a low molecular weight dermatan sulfate: comparison with unfractionated dermatan sulfate.
    Dol F, Petitou M, Lormeau JC, Choay J, Caranobe C, Sie P, Saivin S, Houin G, Boneu B.
    J Lab Clin Med; 1990 Jan 01; 115(1):43-51. PubMed ID: 2299256
    [Abstract] [Full Text] [Related]

  • 46. Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma.
    Okwusidi JI, Anvari N, Kulczycky M, Blajchman MA, Buchanan MR, Ofosu FA.
    J Lab Clin Med; 1991 May 01; 117(5):359-64. PubMed ID: 2019790
    [Abstract] [Full Text] [Related]

  • 47. Human platelet factor 4 and protamine sulphate interaction with glycosaminoglycans in the rabbit.
    Cella G, Myers CJ, Prosdocimi M, Sasahara AA.
    Eur J Clin Invest; 1987 Dec 01; 17(6):548-54. PubMed ID: 3123254
    [Abstract] [Full Text] [Related]

  • 48. Anticoagulant mechanisms of Orgaran (Org 10172) and its fraction with high affinity to antithrombin III (Org 10849).
    Ofosu FA.
    Haemostasis; 1992 Dec 01; 22(2):66-72. PubMed ID: 1379966
    [Abstract] [Full Text] [Related]

  • 49. Source-induced fragmentation of heparin, heparan, and galactosaminoglycans and application.
    Hu P, Fang L, Chess EK.
    Anal Chem; 2009 Mar 15; 81(6):2332-43. PubMed ID: 19228018
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. A non-hemorrhagic hybrid heparin/heparan sulfate with anticoagulant potential.
    Brito AS, Cavalcante RS, Palhares LC, Hughes AJ, Andrade GP, Yates EA, Nader HB, Lima MA, Chavante SF.
    Carbohydr Polym; 2014 Jan 15; 99():372-8. PubMed ID: 24274520
    [Abstract] [Full Text] [Related]

  • 52. Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers.
    Harenberg J, Jeschek M, Acker M, Malsch R, Huhle G, Heene DL.
    Blood Coagul Fibrinolysis; 1996 Jan 15; 7(1):49-56. PubMed ID: 8845462
    [Abstract] [Full Text] [Related]

  • 53. Thromboelastometry fails to detect autoheparinization after major trauma and hemorrhagic shock.
    Zipperle J, Oberladstätter D, Weichselbaum N, Schlimp CJ, Hofmann N, Iapichino G, Voelckel W, Ziegler B, Grottke O, Osuchowski M, Schöchl H.
    J Trauma Acute Care Surg; 2022 Mar 01; 92(3):535-541. PubMed ID: 34789706
    [Abstract] [Full Text] [Related]

  • 54. Time courses of the antithrombotic effects, bleeding enhancing effects and interactions with factors Xa and thrombin after administration of low molecular weight heparinoid Org 10172 or heparin to rats.
    Hobbelen PM, Vogel GM, Meuleman DG.
    Thromb Res; 1987 Dec 01; 48(5):549-58. PubMed ID: 3481660
    [Abstract] [Full Text] [Related]

  • 55. Anticoagulant and antithrombotic actions of a semisynthetic beta-1,3-glucan sulfate.
    Alban S, Jeske W, Welzel D, Franz G, Fareed J.
    Thromb Res; 1995 May 01; 78(3):201-10. PubMed ID: 7631300
    [Abstract] [Full Text] [Related]

  • 56. Osmotic stress regulates the anticoagulant efficiency of dermatan sulfate.
    McGee MP, Wagner W, Li L.
    Matrix Biol; 2004 Oct 01; 23(6):363-70. PubMed ID: 15533757
    [Abstract] [Full Text] [Related]

  • 57. Structural and conformational aspects of the anticoagulant and anti-thrombotic activity of heparin and dermatan sulfate.
    Casu B, Guerrini M, Torri G.
    Curr Pharm Des; 2004 Oct 01; 10(9):939-49. PubMed ID: 15078125
    [Abstract] [Full Text] [Related]

  • 58. Antithrombotic and anticomplementary properties of a very low molecular mass dermatan sulfate.
    Fabiana Alberto M, Giaquinta Romero D, Lazzari M, Calabrese GC.
    Thromb Res; 2008 Oct 01; 122(1):109-16. PubMed ID: 17936880
    [Abstract] [Full Text] [Related]

  • 59. Dermatan sulfate and LMW heparin enhance the anticoagulant action of activated protein C.
    Fernández JA, Petäjä J, Griffin JH.
    Thromb Haemost; 1999 Nov 01; 82(5):1462-8. PubMed ID: 10595639
    [Abstract] [Full Text] [Related]

  • 60. Antithrombotic activity of dermatan sulfate in heparin cofactor II-deficient mice.
    Vicente CP, He L, Pavão MS, Tollefsen DM.
    Blood; 2004 Dec 15; 104(13):3965-70. PubMed ID: 15315969
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.